Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Open accessThe DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis. However, this combined approach provides correct therapeutic and prognostic information in only 50 percent of cases. METHODS: We determined the gene-expression profiles in samples of peripheral blood or bone marrow from 285 patients with AML using Affymetrix U133A GeneChips containing approximately 13,000 unique genes or expression-signature tags. Data analyses were carried out with Omniviz, significance analysis of microarrays, and prediction analysis of microarrays software. Statistical analyses were performed to determine the prognostic significance of cases of AML with specific molecular signatures. RESULTS: Unsupervised cluster analyses identified 16 groups of patients with AML on the basis of molecular signatures. We identified the genes that defined these clusters and determined the minimal numbers of genes needed to identify prognostically important clusters with a high degree of accuracy. The clustering was driven by the presence of chromosomal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular genetic mutations (CEBPA), and abnormal oncogene expression (EVI1). We identified several novel clusters, some consisting of specimens with normal karyotypes. A unique cluster with a distinctive gene-expression signature included cases of AML with a poor treatment outcome. CONCLUSIONS: Gene-expression profiling allows a comprehensive classification of AML that includes previously identified genetically defined subgroups and a novel cluster with an adverse prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Diagnosis of multiple cancer types by shrunken centroids of gene expression
Tibshirani, R., Hastie, T., Narasimhan, B., & Chu, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082099299 · Cited by 2,930
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723 · cited 2×
“(%) <35 yr 35–60 yr ≥60 yr 76 (27) 177 (62) 32 (11)”
BackgroundSlovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558 · cited 2×
“(%)* t(15;17) t(8;21) inv(16)/t(16;16) +8 +11 +21 ¡5 ¡5(q) ¡7 ¡7(q) 3q t(6;9) t(9;22) t(11q23) Complex karyotype (>3 chromosomal abnormalities) Other abnormal karyotypes Normal karyotype Not determined 18 (6) 22 (8) 19 (7) 26 (9) 7 (2) 2 (1) 3 (1) 1 (<1) 13 (5) 7 (2) 6 (2) 4 (1) 2 (1) 19 (7) 11 (4) 60 (21) 119 (42) 10…”
Research works printed but not linked: 1
- 17. Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. Blood (in press).
Cited by
Items 201–300 of 1,000
Peripheral blood gene expression profiling for cardiovascular disease assessment
Aziz, H., Zaas, A. K., & Ginsburg, G. S. (2007) · Genomic Medicine · doi:10.1007/s11568-008-9017-x · Cited by 114
“…sclerosis (Bomprezzi et al. 2003; Singh et al. 2007), asthma (Brutsche et al. 2002), solid malignancies (Alizadeh et al. 2000; Golub et al. 1999; Valk et al. 2004), solid organ transplantation (Baron et al. 2007; Horwitz et al. 2004), as well as environmental exposures (Lodovici et al. 2007;…”
Backgroundde Jonge, H. J. M., Woolthuis, C. M., Vos, A., Mulder, A. B., van den Berg, E., Kluin, P. M., van der Weide, K., de Bont, E. S. J. M., Huls, G. A., Vellenga, E., et al. (2011) · Leukemia · doi:10.1038/leu.2011.172 · Cited by 112
“; unfavorable risk: inv(3) or t(3;3), t(6;9), t(v;11)(v;q23) other than t(9;11), -5 or del(5q), -7, abn(17p), complex karyotype (three or more abnormalities in the absence of a WHO designated recurring chromosome abnormality); intermediate risk: all chromosome abnormalities not classified as favorable or unfavorable.”
BackgroundTidball, J. G., & Wehling‐Henricks, M. (2005) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000179948.65895.1a · Cited by 109
Machine-learned cluster identification in high-dimensional data
Ultsch, A., & Lötsch, J. (2016) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2016.12.011 · Cited by 112
Environmental and Societal Impact of Nanotechnology
Babatunde, D. E., Denwigwe, I. H., Babatunde, O. M., Gbadamosi, S. L., Babalola, I. P., & Agboola, O. (2019) · IEEE Access · doi:10.1109/access.2019.2961513 · Cited by 121
“Similar chips for the diagnosis of leukaemias, mouth and throat tumours are being developed [79]–[81].”
Bill, M., Mrózek, K., Kohlschmidt, J., Eisfeld, A., Walker, C. J., Nicolet, D., Papaioannou, D., Blachly, J. S., Orwick, S. J., Carroll, A. J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014732117 · Cited by 109
Age-Specific Differences in Oncogenic Pathway Dysregulation in Patients With Acute Myeloid Leukemia
Rao, A. V., Valk, P. J. M., Metzeler, K. H., Acharya, C. R., Tuchman, S. A., Stevenson, M. M., Rizzieri, D. A., Delwel, R., Buske, C., Bohlander, S. K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2547 · Cited by 104
Self-citationProtein kinase Cι expression and oncogenic signaling mechanisms in cancer
Murray, N. R., Kalari, K. R., & Fields, A. P. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22463 · Cited by 115
“Significant overexpression of PKCi was also detected in renal cancer (Gumz et al., 2007), bladder cancer (Dyrskjot et al., 2004; Sanchez-Carbayo et al., 2006), melanoma (Talantov et al., 2005) and leukemia (Valk et al., 2004) (Table 2).”
BackgroundMartens, J. H. A., Mandoli, A., Simmer, F., Wierenga, B.-J., Saeed, S., Singh, A. A., Altucci, L., Vellenga, E., & Stunnenberg, H. G. (2012) · Blood · doi:10.1182/blood-2012-05-429050 · Cited by 103
Baldus, C. D., Mrózek, K., Marcucci, G., & Bloomfield, C. D. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06566.x · Cited by 102
“…applied to identify expression signatures that could predict clinical outcome within this heterogeneous cohort of patients (Bullinger et al, 2004; Valk et al, 2004). ª 2007 The Authors 394 Journal Compilation ª 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, 387–400 In a…”
BackgroundProspective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones
de Boer, B., Prick, J. C. M., Pruis, M. G. M., Keane, P., Imperato, M. R., Jaques, J., Brouwers-Vos, A. Z., Hogeling, S. M., Woolthuis, C. M., Nijk, M. T., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.014 · Cited by 106
Sun, H., Lin, D., Guo, X., Masouleh, B. K., Gery, S., Cao, Q., Alkan, S., Ikezoe, T., Akiba, C., PAQUETTE, R. L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7702 · Cited by 107
“Valk [88].”
Current Methodological Issues in the Economic Assessment of Personalized Medicine
Annemans, L., Redekop, K., & Payne, K. (2013) · Value in Health · doi:10.1016/j.jval.2013.06.008 · Cited by 105
An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML
Bullinger, L., Döhner, K., Kranz, R., Stirner, C., Fröhling, S., Scholl, C., Kim, Y. H., Schlenk, R. F., Tibshirani, R., Döhner, H., et al. (2008) · Blood · doi:10.1182/blood-2007-09-115055 · Cited by 98
“Age,* y median (range) 43 (16-60) 49 (27-60)”
Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10
Oakley, K., Han, Y., Vishwakarma, B. A., Chu, S., Bhatia, R., Gudmundsson, K. O., Keller, J. R., Chen, X., Vasko, V. V., Jenkins, N. A., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388710 · Cited by 105
Sunde, J. S., Donninger, H., Wu, K., Johnson, M. E., Pestell, R. G., Rose, G. S., Mok, S. C., Brady, J. N., Bonome, T., & Birrer, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0683 · Cited by 99
Chemical Inhibition of ENL/AF9 YEATS Domains in Acute Leukemia
Garnar-Wortzel, L., Bishop, T. R., Kitamura, S., Milosevich, N., Asiaban, J. N., Zhang, X., Zheng, Q., Chen, E., Ramos, A. R., Ackerman, C. J., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01550 · Cited by 100
Khaznadar, Z., Boissel, N., Agaugué, S., Henry, G., Cheok, M. H.-C., Vignon, M., Géromin, D., Cayuela, J., Castaigné, S., Pautas, C., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500262 · Cited by 101
“(18), Cluster5 had an intermediate OS and relapse-free survival, whereas no information about clinical outcome was provided for Cluster7.”
BackgroundThe `dnet¿ approach promotes emerging research on cancer patient survival
Fang, H., & Gough, J. (2014) · Genome Medicine · doi:10.1186/preaccept-1248435140128963 · Cited by 96
“Conventional research into survivalness has focused on individual tumour types, wherein cancer patients of the same type are first stratified into subtypes according to genomic data (mostly expression data [5-9], and now mutation data [10]), and then are correlated with survival data in the hope of discovering clinica…”
BackgroundDou, X., Xiao, Y., Shen, C., Wang, K., Wu, T., Liu, C., Li, Y., Yu, X., Liu, J., Dai, Q., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01213-w · Cited by 90
A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects
Wouters, B. J., Löwenberg, B., & Delwel, R. (2008) · Blood · doi:10.1182/blood-2008-04-153239 · Cited by 105
Self-citationBard-Chapeau, E. A., Jeyakani, J., Kok, C. H., Muller, J., Chua, B. Q., Gunaratne, J., Batagov, A., Jenjaroenpun, P., Kuznetsov, V. A., Wei, C.-L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119229109 · Cited by 97
“Strikingly, among 16 clusters representing distinctive gene expression signatures identified from 285 acute myeloid leukemia patients (24), only one cluster, c10 (the only one linked to abnormal EVI1 expression), showed significant correlation with our EVI1 target genes (Fig.”
BackgroundGutiérrez, N. C., López-Pérez, R., Hernández, J. M., Isidro, I., González, B., Delgado, M., Fermiñán, E., García, J. L., Vázquez, L., González, M., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403625 · Cited by 71
A Proteomics and Transcriptomics Approach to Identify Leukemic Stem Cell (LSC) Markers
Bonardi, F., Fusetti, F., Deelen, P., van Gosliga, D., Vellenga, E., & Schuringa, J. J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.021931 · Cited by 98
EVI1 and hematopoietic disorders: History and perspectives
Nucifora, G., Laricchia‐Robbio, L., & Senyuk, V. I. (2005) · Gene · doi:10.1016/j.gene.2005.09.020 · Cited by 96
Repression of Bone Morphogenetic Protein and Activin-inducible Transcription by Evi-1
Alliston, T., Ko, T. C., Cao, Y., Liang, Y.-Y., Feng, X.-H., Chang, C., & Derynck, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414305200 · Cited by 96
C/EBPα and the pathophysiology of acute myeloid leukemia
Mueller, B. U., & Pabst, T. (2005) · Current Opinion in Hematology · doi:10.1097/01.moh.0000190110.08156.96 · Cited by 112
Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia
Meshinchi, S., & Arceci, R. J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-3-341 · Cited by 97
Vitamin B6 Addiction in Acute Myeloid Leukemia
Chen, C.-C., Li, B., Millman, S. E., Chen, C., Li, X., Morris, J. P., Mayle, A., Ho, Y.-J., Loizou, E., Liu, H., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.002 · Cited by 103
“CRISPR/Cas9 sgRNA library construction and functional genomics screen— The expression levels of all the genes in both AML leukemic cells and CD34+ normal hematopoietic stem and progenitor cells were downloaded from previously published report (Valk et al., 2004).”
MethodThe Noncanonical WNT Pathway Is Operative in Idiopathic Pulmonary Arterial Hypertension
Laumanns, I. P., Fink, L., Wilhelm, J., Wolff, J.-C., Mitnacht‐Kraus, R., Graef-Hoechst, S., Stein, M. M., Bohle, R. M., Klepetko, W., Hoda, M. A. R., et al. (2009) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0153oc · Cited by 99
Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia
Grubach, L., Juhl‐Christensen, C., Rethmeier, A., Olesen, L. H., Aggerholm, A., Hokland, P., & Østergaard, M. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01083.x · Cited by 99
“The functional role of this PcG member has not yet been elucidated, but it has been found to exhibit a high expression in AML patients with t(8;21) (14).”
BackgroundKohlmann, A., Schoch, C., Dugas, M., Schnittger, S., Hiddemann, W., Kern, W., & Haferlach, T. (2005) · Leukemia · doi:10.1038/sj.leu.2403746 · Cited by 100
Wey, S., Luo, B., Tseng, C.-C., Ni, M., Zhou, H., Fu, Y., Bhojwani, D., Carroll, W. L., & Lee, A. S. (2011) · Blood · doi:10.1182/blood-2011-06-357384 · Cited by 94
Gough, S. M., Lee, F., Yang, F., Walker, R. L., Zhu, Y. J., Pineda, M. A., Onozawa, M., Chung, Y. J., Bilke, S., Wagner, E. K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0419 · Cited by 90
“AML patient clusters 2 and 6 (22) showed markedly increased levels of BAHCC1 compared to both normal BM and CD34 cells,”
Negrotto, S., Ng, K. P., Jankowska, A. M., Bodo, J., Gopalan, B., Guinta, K., Mulloy, J. C., Hsi, E., Maciejewski, J., & Saunthararajah, Y. (2012) · Leukemia · doi:10.1038/leu.2011.207 · Cited by 90
Figueroa, M. E., Wouters, B. J., Skrabanek, L., Glass, J., Li, Y., Erpelinck-Verschueren, C. A. J., Langerak, A. W., Löwenberg, B., Fazzari, M., Greally, J. M., et al. (2009) · Blood · doi:10.1182/blood-2008-08-172387 · Cited by 91
Self-citationCore Binding Factor Acute Myeloid Leukemia
Paschka, P. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.011 · Cited by 100
A concise review on the molecular genetics of acute myeloid leukemia
Padmakumar, D., Chandraprabha, V. R., Gopinath, P., Devi, A. R. T. V., Anitha, G. R. J., Sreelatha, M. M., Padmakumar, A., & Sreedharan, H. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106727 · Cited by 100
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years
Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Wierda, W. G., Faderl, S. H., Garcia‐Manero, G., Issa, J. J., Estey, E. H., Keating, M. J., & Freireich, E. J. (2008) · Cancer · doi:10.1002/cncr.23655 · Cited by 99
“Gene expression profiling in AML may identify new AML subsets with different prognoses or define new therapeutic targets.(52,53) Detection of minimal residual disease in AML and ALL in mor-”
BackgroundHorton, S. J., Jaques, J., Woolthuis, C. M., van Dijk, J., Mesuraca, M., Huls, G. A., Morrone, G., Vellenga, E., & Schuringa, J. J. (2012) · Leukemia · doi:10.1038/leu.2012.343 · Cited by 98
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia
Mrózek, K., Marcucci, G., Paschka, P., & Bloomfield, C. D. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32831369df · Cited by 89
An Integrative Genomic and Epigenomic Approach for the Study of Transcriptional Regulation
Figueroa, M. E., Reimers, M., Thompson, R. F., Ye, K., Li, Y., Selzer, R. R., Fridriksson, J., Paietta, E., Wiernik, P., Green, R. D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001882 · Cited by 87
“[17–20]).”
Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells
Arai, S., Yoshimi, A., Shimabe, M., Ichikawa, M., Nakagawa, M. M., Imai, Y., Goyama, S., & Kurokawa, M. (2010) · Blood · doi:10.1182/blood-2009-07-234310 · Cited by 97
Porter, C. C., Kim, J., Fosmire, S., Gearheart, C. M., van Linden, A., Baturin, D., Zaberezhnyy, V, Patel, P. R., Gao, D., Tan, A. C., et al. (2012) · Leukemia · doi:10.1038/leu.2011.392 · Cited by 87
“Three datasets are available in this database from which gene expression in AML cells can be compared to “normal” cells (32–34).”
de Bock, C. E., Ardjmand, A., Molloy, T. J., Bone, S., Johnstone, D. M., Campbell, D. M., Shipman, K. L., Yeadon, T. M., Holst, J., Spanevello, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.319 · Cited by 92
EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia
Balgobind, B. V., Lugthart, S., Hollink, I. H. I. M., Arentsen-Peters, S. T. C. J. M., van Wering, E. R., de Graaf, S. S. N., Reinhardt, D., Creutzig, U., Kaspers, G. J. L., de Bont, E. S. J. M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.47 · Cited by 97
“These cases were often split among different clusters harboring MLL -rearranged AML (adult and pediatric AML), monosomy 7s3q26 aberrations (adult AML), or FAB-M6sM7 (pediatric AML)”
BackgroundSelf-citationFrench, P. J., Peeters, J. K., Horsman, S., Duijm, E. J., Siccama, I., van den Bent, M. J., Luider, T. M., Kros, J. M., van der Spek, P. J., & Smitt, P. A. E. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2869 · Cited by 98
“according to the algorithm present in Omniviz software as described (20).”
MethodETS transcription factors as emerging drug targets in cancer
Hsing, M., Wang, Y. Z., Rennie, P. S., Cox, M., & Cherkasov, A. R. (2019) · Medicinal Research Reviews · doi:10.1002/med.21575 · Cited by 100
“Gene expression analysis in a large panel of AML patient samples demonstrated that ERG is highly expressed in most AML patients, and the increased ERG expression is associated with poor prognosis.(25,88,89) Furthermore, it has been shown that shRNA‐mediated silencing of ERG expression inhibited growth of human AML cel…”
BackgroundEVI1 is critical for the pathogenesis of a subset of MLL-AF9–rearranged AMLs
Bindels, E. M. J., Havermans, M., Lugthart, S., Erpelinck, C., Wocjtowicz, E., Krivtsov, A. V., Rombouts, E., Armstrong, S. A., Taskesen, E., Haanstra, J. R., et al. (2012) · Blood · doi:10.1182/blood-2011-11-393827 · Cited by 82
Self-citationDunne, J., Cullmann, C., Ritter, M., Martinez-Soria, N., Drescher, B., Debernardi, S., Skoulakis, S., Hartmann, O., Krause, M., Krauter, J., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209638 · Cited by 94
“High expression of BAALC as well as low expression of either AZU1, PRG2 or RNASE2 correlate with a poor treatment outcome of AML (Baldus et al., 2003a, b; Bullinger et al., 2004; Valk et al., 2004).”
BackgroundMaintenance of the hematopoietic stem cell pool in bone marrow niches by EVI1-regulated GPR56
Saito, Y., Kaneda, K., Suekane, A., Ichihara, E., Nakahata, S., Yamakawa, N., Nagai, K., Mizuno, N., Kogawa, K., Miura, I., et al. (2013) · Leukemia · doi:10.1038/leu.2013.75 · Cited by 85
Mrózek, K., Döhner, H., & Bloomfield, C. D. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32801684c7 · Cited by 84
Cancer progression by non‐clonal chromosome aberrations
Heng, H. H., Bremer, S. W., Stevens, J. B., Ye, K. J., Miller, F. W., Liu, G., & Ye, C. J. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20964 · Cited by 84
“For instance, a category one type cancer, microarray analysis can generate expression profiling useful to classify the stages and subtypes of genome types, as specific translocations are linked to specific signatures [Valk et al., 2004].”
BackgroundGene-expression profiles and their association with drug resistance in adult acute myeloid leukemia.
Heuser, M., Wingen, L. U., Steinemann, D., Cario, G., Neuhoff, N. V., Tauscher, M., Bullinger, L., Krauter, J., Heil, G., Döhner, H., et al. (2005) · PubMed · Cited by 84
Hartmann, U., Brümmendorf, T. H., Balabanov, S., Thiede, C., Illme, T., & Schaich, M. A. (2005) · PubMed · Cited by 91
Tourneur, L., Delluc, S., Lévy, V., Valensi, F., Radford-Weiss, I., Legrand, O., Vargaftig, J., Boix, C., Macintyre, E. A., Varet, B., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2361 · Cited by 76
“Thus, it is probable that this new marker will not be identified by techniques targeting gene expression, including complementary DNA microarrays (32, 33).”
Diffner, E., Beck, D., Gudgin, E. J., Thoms, J. A. I., Knezevic, K., Pridans, C., Foster, S., Goode, D. K., Lim, W. K., Boelen, L., et al. (2013) · Blood · doi:10.1182/blood-2012-07-446120 · Cited by 83
“CN-AML patients who lack gross genomic alterations can be categorized into clinically relevant prognostic groups based on the mutational status of FLT3, NPM1, and CEBPa.(18,19) Individuals with low molecular risk (LMR; NPM1 mut, FLT3 wt) are considered to have a favorable prognosis and receive standard therapy, wherea…”
Handschuh, L., Kaźmierczak, M., Milewski, M., ralski, M. G. ⁄., Łuczak, M., Wojtaszewska, M. L., Uszczyńska-Ratajczak, B., Lewandowski, K. C., Komarnicki, M. A., & Figlerowicz, M. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4233 · Cited by 96
“Microarray analyses of AML usually result in the clear separation of AML M3 (APL) and AML with the most frequent cytogenetic aberrations (42,21,22).”
The power and potential of integrated diagnostics in acute myeloid leukaemia
Haferlach, T., & Schmidts, I. (2019) · British Journal of Haematology · doi:10.1111/bjh.16360 · Cited by 90
Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia
Ottema, S., Mulet‐Lazaro, R., Beverloo, H. B., Erpelinck-Verschueren, C. A. J., van Herk, S., van der Helm, R. M., Havermans, M., Grob, T., Valk, P. J. M., Bindels, E. M., et al. (2020) · Blood · doi:10.1182/blood.2019003701 · Cited by 90
Self-citationMN1 overexpression is an important step in the development of inv(16) AML
Carella, C., Bonten, J., Sirma, S., Kranenburg, T. A., Terranova, S., Geltink, R. I. K., Shurtleff, S. A., Downing, J. R., Zwarthoff, E. C., Liu, P. P., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404778 · Cited by 87
Heuser, M., Sly, L. M., Argiropoulos, B., Kuchenbauer, F., Lai, C., Weng, A., Leung, M., Lin, G., Brookes, C., Fung, S., et al. (2009) · Blood · doi:10.1182/blood-2009-06-227603 · Cited by 77
Self-citationProgress in the treatment of acute myeloid leukemia
Ravandi, F., Burnett, A. K., Agura, E. D., & Kantarjian, H. M. (2007) · Cancer · doi:10.1002/cncr.23000 · Cited by 79
Goyama, S., Nitta, E., Yoshino, T., Kako, S., Watanabe‐Okochi, N., Shimabe, M., Imai, Y., Takahashi, K., & Kurokawa, M. (2009) · Leukemia · doi:10.1038/leu.2009.202 · Cited by 90
Harousseau, J., Shaughnessy, J. D., & Richardson, P. G. G. (2004) · Hematology · doi:10.1182/asheducation-2004.1.237 · Cited by 106
Rodrigues, N. P., Tipping, A. J., Wang, Z., & Enver, T. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.12.004 · Cited by 87
“In poor prognosis AML, GATA-2 overexpression also mirrors that of Evi-1 overexpression; Evi-1 is also a well established marker of poor prognosis AML and a critical regulator of both HSC and leukemic stem cell (LSC) function and GATA-2 is a target gene of Evi-1 in both HSCs and LSCs (Goyama et al., 2008; Valk et al.,…”
BackgroundSemi-Supervised Domain Adaptation by Covariance Matching
Li, L., & Zhang, Z. (2018) · IEEE Transactions on Pattern Analysis and Machine Intelligence · doi:10.1109/tpami.2018.2866846 · Cited by 85
“[36].”
Human nutrigenomics of gene regulation by dietary fatty acids
Afman, L. A., & Müller, M. M. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.11.005 · Cited by 89
“Whole genome transcriptome analyzes of PBMCs have been applied successfully in discriminating disease from healthy populations and in differentiating several phases/diagnostics of disease [18,19].”
MethodLavallée, V., Krošl, J., Lemieux, S., Boucher, G., Gendron, P., Pabst, C., Boivin, I., Marinier, A., Guidos, C. J., Meloche, S., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705053 · Cited by 79
Cheng, W., Li, J., Zhu, Y., Lin, X., Wen, L., Zhang, F., Zhang, Y., Zhao, M., Fang, H., Wang, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211429119 · Cited by 89
“Inconsistent clustering results and complex cellular compositions have been observed in previous works (8, 18, 19).”
ResultClinically useful prognostic factors in acute myeloid leukemia
Ferrara, F., Palmieri, S., & Leoni, F. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.09.008 · Cited by 78
Andersson, A., Edén, P., Lindgren, D., Nilsson, J. S., Lassen, C., Heldrup, J., Fontes, M., Borg, Å., Mitelman, F., Johansson, B., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403749 · Cited by 88
Co-clustering phenome–genome for phenotype classification and disease gene discovery
Hwang, T., Atluri, G., Xie, M., Dey, S., Hong, C., Kumar, V., & Kuang, R. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks615 · Cited by 84
Bresolin, S., Zecca, M., Flotho, C., Trentin, L., Zangrando, A., Sainati, L., Starý, J., Moerloose, B. D., Hasle, H., Niemeyer, C. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4426 · Cited by 83
Review: Aberrant EVI 1 expression in acute myeloid leukaemia
Hinai, A. S. A. A., & Valk, P. J. M. (2016) · British Journal of Haematology · doi:10.1111/bjh.13898 · Cited by 84
Self-citationClassification of myeloid neoplasms: a comparative review
McManus, P. M. (2005) · Veterinary Clinical Pathology · doi:10.1111/j.1939-165x.2005.tb00042.x · Cited by 85
Nanomaterials in medicine – An overview
Damodharan, J. (2020) · Materials Today Proceedings · doi:10.1016/j.matpr.2020.05.380 · Cited by 97
C/EBPα deregulation as a paradigm for leukemogenesis
Pulikkan, J. A., Tenen, D. G., & Behre, G. (2017) · Leukemia · doi:10.1038/leu.2017.229 · Cited by 79
The Role of the HOXA Gene Family in Acute Myeloid Leukemia
Chen, S., Qin, Z.-Y., Hu, F., Wang, Y., Dai, Y., & Liang, Y. (2019) · Genes · doi:10.3390/genes10080621 · Cited by 86
“Gene Types of leukemia vs. Normal Samples Fold Change P Value t-Test Reference HOXA1 Acute Myeloid Leukemia vs. Normal 3.451 1.95E-07 9.046 Valk [23] Acute Adult T-Cell Leukemia/Lymphoma vs. Normal 10.084 3.46E-05 7.407 Choi [24] HOXA2 NA NA NA NA HOXA3 Acute Myeloid Leukemia vs. Normal 2.230 2.48E-68 19.863 Haferlach…”
InfluentialXiong, X., Liu, J.-M., Qiu, X., Pan, F., Yu, S.-B., & Chen, X. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.141 · Cited by 75
Leukemia Stem Cells in Acute Myeloid Leukemia
Chan, W.-I., & Huntly, B. J. P. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.003 · Cited by 87
Hollink, I. H. I. M., van den Heuvel‐Eibrink, M. M., Arentsen-Peters, S. T. C. J. M., Zimmermann, M., Peeters, J. K., Valk, P. J. M., Balgobind, B. V., Sonneveld, E., Kaspers, G. J. L., de Bont, E. S. J. M., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.031336 · Cited by 86
Self-citationLavallée, V., Lemieux, S., Boucher, G., Gendron, P., Boivin, I., Armstrong, R. N., Sauvageau, G., & Hébert, J. (2016) · Blood · doi:10.1182/blood-2016-03-703868 · Cited by 75
The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops
Ottema, S., Mulet‐Lazaro, R., Erpelinck-Verschueren, C. A. J., van Herk, S., Havermans, M., Varea, A. A., Vermeulen, M., Beverloo, H. B., Gröschel, S., Haferlach, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25862-3 · Cited by 77
Self-citationAML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches
Hatlen, M. A., Wang, L., & Nimer, S. D. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0206-6 · Cited by 81
“The unsupervised clustering of microarray data has allowed for the identification of leukemia subgroups, such as t(8;21) positive AML and CBFβ rearranged [inv(16) and t(16;16)] AML, based upon distinct gene expression signatures [75,76].”
Backgroundvan Doorn-Khosrovani, S. B. V. W., Spensberger, D., de Knegt, Y., Tang, M., Löwenberg, B., & Delwel, R. (2005) · Oncogene · doi:10.1038/sj.onc.1208588 · Cited by 80
“Previously, we had determined gene expression profiles of 285 AML cases (Valk et al., 2004), which included the 77 cases that were investigated in the present study.”
Self-citationMolecular prognostication of liver cancer: End of the beginning
Thorgeirsson, S. S., Lee, J., & Grisham, J. W. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.01.008 · Cited by 77
“Indeed, microarray-based global gene expression analysis of human tumors has already revealed the identification of gene expression patterns or signatures related to tumor classification, prognosis and response to therapy [7–14].”
BackgroundDebey, S., Zander, T., Brors, B., Popov, A., Eils, R., & Schultze, J. L. (2006) · Genomics · doi:10.1016/j.ygeno.2005.11.010 · Cited by 73
“In fact, numerous landmark studies, particularly in cancer research, have highlighted the power of this technology to improve molecular diagnostics [3–6], prediction of prognosis at diagnosis [7–11], and even prediction of drug efficacy [12–14].”
BackgroundHoming and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C
Schwieger, M., Schüler, A., Forster, M., Engelmann, A., Arnold, M., Delwel, R., Valk, P. J. M., Löhler, J., Slany, R. K., Olson, E. N., et al. (2009) · Blood · doi:10.1182/blood-2008-05-158196 · Cited by 77
Self-citationRole of Transcription Factors C/EBPa and PU.1 in Normal Hematopoiesis and Leukemia
Koschmieder, S., Rosenbauer, F., Steidl, U., Owens, B. M., & Tenen, D. G. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05051 · Cited by 72
“The most frequently encountered translocation products involving transcription factor genes in AML are AML1/ETO [t(8;21)] in 7% to 8% of all patients, CBF� / MYH11 [inv(16)] in 5% to 7% of patients, translocations involving the MLL gene [located on 11q23] in 4% to 7% of patients, and PML/RAR� [t(15;17)] in 6% to 7% of…”
BackgroundGardini, A., Cesaroni, M., Luzi, L., Okumura, A. J., Biggs, J. R., Minardi, S. P., Venturini, E., Zhang, D., Pelicci, P. G., & Alcalay, M. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000275 · Cited by 78
“(C) Box-plot representing expression levels in AML samples of AML1/ETO target genes identified by ChIP-chip and expression profiling (approximately 70% of these were included in the array used for the study [28]).”
BackgroundClass prediction models of thrombocytosis using genetic biomarkers
Gnatenko, D. V., Zhu, W., Xu, X., Samuel, E. T., Monaghan, M., Zarrabi, M. H., Kim, C., Dhundale, A., & Bahou, W. F. (2009) · Blood · doi:10.1182/blood-2009-05-224477 · Cited by 75
KDM1 class flavin‐dependent protein lysine demethylases
Burg, J. M., Link, J. E., Morgan, B. S., Heller, F. J., Hargrove, A. E., & McCafferty, D. G. (2015) · Biopolymers · doi:10.1002/bip.22643 · Cited by 76
Overexpression of N-Myc Rapidly Causes Acute Myeloid Leukemia in Mice
Kawagoe, H., Kandilci, A., Kranenburg, T. A., & Grosveld, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1118 · Cited by 70
“The most likely explanation for why N-MYC overexpression in AML was not reported in two large-scale expression array analyses (17, 35 ) is that in those studies, gene expression profiles from different AML subtypes were compared with each other and not with normal CD34+ cells.”
Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia
Glass, C., Wuertzer, C. A., Cui, X., Bi, Y., Davuluri, R. V., Xiao, Y.-Y., Wilson, M. P., Owens, K. M., Zhang, Y., & Perkins, A. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067134 · Cited by 71
“In addition to blocked differentiation, Evi1 leukemic cells also demonstrate resistance to apoptosis which has been associated with ineffectiveness of chemotherapy regimens, high relapse rates and poor prognosis [39].”
BackgroundZucknick, M., Richardson, S. T., & Stronach, E. A. (2008) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1307 · Cited by 81
Hsu, J. B., Chang, T., Lee, G. A., Lee, T.-Y., & Chen, C. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0479-6 · Cited by 78
“On the other hand, previous studies have shown that gene expression profiling provides an objective method to classify tumors [11, 12]; it is better to correlate gene expression profiling, rather than tumor histology, with prognosis [13].”
BackgroundBiology and management of relapsed acute myeloid leukaemia
Craddock, C., Tauro, S., Moss, P. A. H., & Grimwade, D. J. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05318.x · Cited by 76
“…identifies characteristic patterns of gene expression in different cytogenetic subgroups and FLT3 ITD-positive AML will be of importance in identifying mechanisms of disease recurrence in patients at a high risk of disease relapse (Schoch et al, 2002; Bullinger et al, 2004; Valk et al, 2004).”
BackgroundJayavelu, A. K., Müller, J. P., Bauer, R., Böhmer, S.-A., Lässig, J., Cerny‐Reiterer, S., Sperr, W. R., Valent, P., Maurer, B., Moriggl, R., et al. (2015) · Leukemia · doi:10.1038/leu.2015.234 · Cited by 78
Gene expression profiling in MDS and AML: potential and future avenues
Theilgaard‐Mönch, K., Boultwood, J., Ferrari, S., Giannopoulos, K., Hernández‐Rivas, J. M., Kohlmann, A., Morgan, M. A., Porse, B. T., Tagliafico, E., Zwaan, C. M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.48 · Cited by 78
Metadata
- Authors
- Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., & Delwel, R.
- Affiliations
- Erasmus MC (NL)
- Leiden University Medical Center (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-15
- Volume
- 350
- Issue
- 16
- Pages
- 1617-1628
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110502951
- Cited by
- 1,370
- References
- 30
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 27 · 2023: 40 · 2022: 30 · 2021: 59 · 2020: 49 · 2019: 50 · 2018: 40 · 2017: 39 · 2016: 66 · 2015: 53 · 2014: 64 · 2013: 72 · 2012: 86
- FWCI
- 63.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Erasmus Medisch Centrum
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- acute myeloid leukemia, gene expression profiling, prognostic stratification, molecular signatures, patient clustering, inv(16), CEBPA mutation, chromosomal abnormalities, normal karyotype, treatment outcomes
- MeSH terms
- Acute Disease, Adult, Algorithms, Chromosome Aberrations, Female, Humans, Karyotyping, Leukemia, Myeloid, Male, Middle Aged, Mutation, Prognosis, Software, Gene Expression, Multivariate Analysis, Cluster Analysis, Survival Analysis, Oligonucleotide Array Sequence Analysis, Cytogenetic Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.